Adrenal suppression and clinical harms by inhaled corticosteroids: a review of safety and guidelines
Canadian Agency for Drugs and Technologies in Health
Record ID 32011001508
English
Authors' results and conclusions:
Guideline recommendations for the use of beclomethasone, ciclesonide, and fluticasone based on potential relative clinical harms were not identified. Studies of durations of up to one year suggest similar overall adverse event rates in BDP versus CIC or FP, however FP may result in more adrenal suppression, overall adverse events including oral candidiasis, and decreased growth velocity compared with CIC. Comparisons of BDP versus CIC with regard to adrenal suppression and growth retardation were not identified. The long-term clinical impact of these findings is unclear.
Details
Project Status:
Completed
URL for project:
http://www.cadth.ca/media/pdf/htis/aug-2011/RC0295_Adrenal_Suppression_Inhaled_Steroids.pdf
Year Published:
2011
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Administration, Inhalation
- Adolescent
- Adrenal Cortex Hormones
- Adrenal Insufficiency
- Adult
- Androstadienes
- Beclomethasone
- Child
- Pregnenediones
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.